Short answer
Eton Pharmaceuticals, Inc. (ETON) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $24M (up 40.4% year over year) with net income of $2M.
Q1 2026 key financials · XBRL
- Revenue
- $24M
- +40.4% YoY
- Net income
- $2M
- +198.9% YoY
- Operating margin
- 9.9%
- Gross margin
- 60.7%
- EPS (diluted)
- $0.05
- +183.3% YoY
Source: XBRL data from the Eton Pharmaceuticals, Inc. (ETON) Q1 2026 10-Q on SEC EDGAR. USD.
Eton Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $24.266M vs $17.282M YoY, gross profit $14.735M vs $9.861M
- GAAP net income $1.554M vs $1.572M loss YoY, basic EPS $0.06 vs $(0.06)
- Product sales growth led by INCRELEX, GALZIN, ALKINDI SPRINKLE, Carglumic Acid, plus KHINDIVI sales
- Cash $19.7M, operating cash flow $7.405M vs $2.090M YoY
- Investing outflows $15.075M, including $14.000M HEMANGEOL rights acquisition and $1.000M licensing payment
Risk Factors
- No risk-factors section provided in the submitted text
- Asset Purchase Agreement with Pierre Fabre dated February 27, 2026 identified as a new transaction
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Eton Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.